DGAP-News: Zyomyx Receives $7.5 Million From UNITAID to

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Mar 26, 2014 at 7:45 AM

DGAP-News: Zyomyx Receives $7.5 Million From UNITAID to Launch Rapid, Service-Free Point-of-Care CD4 Test

DGAP-News: Zyomyx / Zyomyx Receives $7.5 Million From UNITAID to Launch Rapid, Service-Free Point-of-Care CD4 Test 26.03.2014 / 12:30 --------------------------------------------------------------------- Quantitative Diagnostic Will Support Expanded Access to HIV Treatment FREMONT, Calif., 2014-03-26 12:30 CET (GLOBE NEWSWIRE) -- Zyomyx, Inc. has been awarded US$7.5 million from UNITAID to commercialize its quantitative MyT4(tm) point-of-care CD4 test, designed to guide HIV/AIDS treatment initiation and monitoring in low- and middle-income countries. UNITAID's funding contribution is part of its strategy to speed up access to a range of new and improved technologies from a number of manufacturers for HIV/AIDS, tuberculosis and malaria for the world's most vulnerable populations. It will support field evaluations of the product, training for national HIV programs, and country-level and global regulatory filings. The Zyomyx test is the fastest point-of-care CD4 diagnostic on the market and delivers results that are equivalent to lab-based flow cytometry, the gold standard of CD4 testing. The MyT4(tm) CD4 test is commercially available receiving a CE Mark in December 2013. 'We are delighted and grateful that UNITAID has recognized the potential of the MyT4(tm) CD4 test and invested its resources to support its introduction,' said Peter Wagner, President and CEO of Zyomyx. 'We are fully aligned with UNITAID's approach to address public health issues as well as the market conditions to bring diagnostic technology to those most in need. UNITAID's innovative use of financing and market power to effect change makes it a transformational player in the global health arena.' CD4 count is the critical marker to determine when patients need to start antiretroviral therapy and to monitor the immune status of HIV positive patients. However, there are barriers to testing for people in resource poor settings because traditional lab tests are only available in central locations and require that many patients wait weeks to obtain a result. The quantitative MyT4(tm) CD4 test provides a result in 10 minutes from a finger-prick sample. The product is the only service-free quantitative test on the market as it does not require any maintenance or swap to a central location for repairs because there is no complex instrumentation. As a result, the cost to adopt the test is minimal compared to thousands of dollars for instrument based platforms. The MyT4(tm) CD4 test supports countries' efforts to decentralize HIV treatment, expanding access to healthcare for remote populations and relieving the burden at centralized facilities. According to WHO, there are 9.7 million people in developing countries on antiretroviral therapy today but another 16 million people are unable to access the treatment they need. Point-of-care diagnostic testing is a critical tool to determine treatment eligibility and link greater numbers of HIV positive people to lifesaving treatment. 'To curb the AIDS epidemic, we must expand access to testing and treatment globally,' said Ben Plumley, CEO of Pangaea Global AIDS Foundation. 'Rapid, affordable and accessible point-of-care CD4 and viral load diagnostics are critical for enabling us to reach vulnerable groups and better identify who needs to initiate or adjust treatment.' The MyT4(tm) CD4 test is the first of an expanding line of diagnostic tests that originate from Zyomyx's portfolio of proprietary platform technologies capable of moving laboratory tests for cells, proteins and infectious agents to the point-of-care and thereby providing immediate benefits to clinicians, healthcare workers and patients in multiple disease areas. About Zyomyx, Inc. Zyomyx, Inc. has developed a proprietary cell capture and analysis platform to enable quick low-cost diagnosis for infectious diseases. The platform is focused on a suite of diagnostics for antibiotic resistance where same day results at the point-of-care have a major impact on treatment outcomes and health care costs. The company's first product, an inexpensive CD4 T-cell point-of-care test, demonstrates the potential of Zyomyx's capture and analysis technology. Zyomyx, which is based in Fremont, California, is privately held. For more information, visit http://www.zyomyx.com. About UNITAID Based in Geneva and hosted by the World Health Organization, UNITAID uses innovative financing to increase funding for greater access to treatments and diagnostics for HIV/AIDS, malaria and tuberculosis in low-income countries. Approximately half of UNITAID's resources come from a small levy on airline tickets in several countries, while the rest is provided primarily by multi-year contributions from governments and a foundation. As of the end of 2011, this levy has collected US$ 1.06 billion - 66% of the US$ 1.6 billion raised by UNITAID. CONTACT: Karen Schlein, 510-456-1749, kschlein@zyomyx.com News Source: NASDAQ OMX End of Corporate News --------------------------------------------------------------------- 26.03.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Zyomyx United States ISIN: US9902941676 End of News DGAP News-Service --------------------------------------------------------------------- 259706 26.03.2014

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lincoln Education Faces Securities Fraud Lawsuit Headwinds

You wake up one morning, check your portfolio, and there it is—a 24.93% nosedive from Lincoln Educational Services Corp. (NASDAQ:LINC). That ain't a typo, my friend. That's reality smacking you right in the face. Now, what's cooking here? Why did this education stock tank, and what should you, as an investor, be doing about it? Well, pull up a chair, and let's dissect...

Deep Principle's Hydrogen-1.0: A Leap in AI-Driven Chemistry

Leaving Old Lab Notebooks in the Dust Deep Principle just shook up the science lab with their latest brainchild, Hydrogen-1.0. We're talking about an AI-driven marvel designed to tackle chemistry and materials research like no traditional lab rat ever could. On November 4, they rolled out this bad boy—an open-weight model fine-tuned to turn vague scientific hunches into...

APEC CEO Summit Marries Innovation and Global Ties

Shenzhen: The Heartbeat of Future Business Shenzhen isn't just a city on the map. It's an exploding innovation powerhouse, a place where global business leaders will rub shoulders this November for the 2026 APEC CEO Summit. This ain't your average conference, my friends. CCPIT (China's national trade pushers) are hosting it from November 17 to 18, promising a powerhouse...

Cheche Group Proposes New Share Class with Heavy Voting Power

Cheche Group: A Real Shake-Up for Investors November 5, 2026—here we have a little whirlwind from Beijing as Cheche Group Inc., a significant insurer dealmaker in China's auto tech world, has stirred up an extraordinary general meeting for November 25th. This isn't just another corporate shindig; we're talking about throwing a new class of shares into the mix—each one...

Real Estate Sage: Tad Barber's Tips on Selling Your Home

Kicking Off the 2027 Home Selling Game Plan Let me tell you, the real estate world isn't for the faint-hearted. It’s a realm where a solid game plan makes a world of difference, especially when you're thinking about selling your home in 2027. In Aiken, South Carolina, it seems the local know-it-all Tad Barber has teamed up with HelloNation to throw down some insight on...

Signature Aviation, JA Partner to Inspire Young Aviators

Signature Aviation and JA Worldwide Join Forces Signature Aviation and Junior Achievement (JA) Worldwide are getting crafty and forming a new partnership, aimed at pulling the curtain back on the aviation industry for high school students. It's all about workforce readiness and carving out career paths, and this is the kind of hands-on stuff that's got legs. It kicks off...

Rice Sets Course in Houston’s Thriving Innovation Hub

Houston's Innovation Scene Expands The ground's barely settled and already Rice University is shaking up the scene in Houston’s Ion District with the Arc. At nearly 200,000 square feet, this powerhouse is set to bridge the gap between research, industry, and entrepreneurs, pushing ideas from discovery to reality. A Groundbreaking Investment For anyone with half an idea...

Mondego Bio Charges Ahead with Cancer Therapy Trials

Cracking Cancer's Code: Mondego's Bold Move Big news from Portugal today—a quiet town called Cantanhede is now the epicenter of a potential game-changer in cancer therapy. Mondego Bio, with its small-molecule innovator MB?388, is diving headfirst into a Phase 1 clinical study. If you're scratching your head about the significance, let me spell it out: this is an attempt...

Nuvoton and Qt Amps Up Graphic Interfaces

By Thomas Cooper Updated Nov 5, 2026 Category News Views 116

Introducing Gerda (TM) IC: Game-Changer Your everyday products just got a whole lot smarter, as Nuvoton Technology Corporation and Qt Group have joined hands to bring a revolutionary graphic interface system—behold, the Gerda (TM) IC. This announcement is just the tip of the iceberg for product developers working within tight budgets. Imagine creating premium graphics...

Global Leaders Unite to Tackle Major World Challenges

Gathering Minds in Washington: A Summit to Remember Let me tell you straight – when over a hundred heavyweights from government, finance, and tech get in the same room, you bet people start paying attention. We’re talking about the 2026 WICE Global Impact Summit that went down at The Penthouse in The Washington Post Building. The movers and shakers weren't there to...